About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Shareholders
Corporate Presentation
Financial Calendar
Regulated Information
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
R&D Day
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Publication of the 2019 Universal Registration Document
Nanobiotix announces first phase I trial with NBTXR3 in pancreatic cancer is safe to proceed per US FDA
6 May 2020
Nanobiotix announces positive first results from phase I expansion in locally advanced head and neck cancer at ASCO 2020
29 May 2020
Publication of the 2019 Universal Registration Document
Published by
Julie Ficheux
on
14 May 2020
No translations available for this page
